World Menopause Day – Information Resources for Perimenopause and Menopause
About Perimenopause and Menopause
Perimenopause, sometimes referred to as the menopausal transition, is a phase in a life characterized by the natural progression toward menopause when menstruation or periods stop permanently. The onset of perimenopause varies, with some people noticing the first signs of this transition in their 40s, while others may experience changes as early as their mid-30s.
During perimenopause, estrogen levels fluctuate irregularly. This hormonal fluctuation can lead to changes in menstrual patterns, including longer or shorter cycles and instances where the ovaries do not release an egg (ovulati...
Source: The Cornflower - October 18, 2023 Category: Databases & Libraries Authors: Bobbi Newman Tags: Public Libraries Resource Sharing health information menopause perimenopause world menopause day Source Type: news
Deborah Barak, Longtime CBS Business Affairs Executive, Dies at 65
Deborah Barak, a longtime CBS business affairs executive who helped guide the Eye network through a transitional era of television, died Saturday after battling cancer. She was 65. Barak was widely respected throughout the industry as a sharp negotiator and a savvy dealmaker. Among the many…#deborahbarak #netflix #westcoast #debby #davidstapf #cbsstudios #amyreisenbach #ninatassler #cbsentertainment #tassler (Source: Reuters: Health)
Source: Reuters: Health - January 22, 2023 Category: Consumer Health News Source Type: news
Genome Spotlight: Fishing cat (Prionailurus viverrinus)
A high-quality reference genome for this vulnerable feline may help scientists understand why they’re so prone to transitional cell carcinoma in captivity. (Source: The Scientist)
Source: The Scientist - December 22, 2022 Category: Science Tags: News & Opinion Source Type: news
Science ’s 2022 Breakthrough of the Year: A telescope’s golden eye sees the universe anew
html { scroll-behavior: smooth; } .news-article-content--featured>.bodySection>.mb-2x:not(:first-of-type) { display: none; } h3 { scroll-margin-top: 5rem; } .parent-section h3, .subsection h3 { font-size: 1.375rem; line-height: 1.875rem; } .news-article-content-footer h2 { display: none; } .toc img { padding-bottom: 16px; transition: opacity .25s; } .toc img:hover { opacity: 60%; } .toc .image-grid img { padding-bottom: 16px; padding-top: 16px; } .image-grid .news-article__figure__image__wrapper:before, .image-grid .news-article__figure__image__wrapper:after { display: none; } .news-article...
Source: ScienceNOW - December 15, 2022 Category: Science Source Type: news
Telix gets pass-through status for Illuccix
Telix Pharmaceuticals has received transitional pass-through payment statu...Read more on AuntMinnie.comRelated Reading:
Monrol to supply Telix with Lu-177 for renal cancer trial
Telix touts rollout of Illuccix PSMA-PET radiotracer
Shine and Telix ink Lu-177 supply deal
Telix secures FDA clearance for prostate cancer PET imaging agent
Telix applauds NCCN radiotracer update (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 1, 2022 Category: Radiology Source Type: news
Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA ® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor
September 17, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1b/2 NORSE (NCT03473743) study evaluating BALVERSA® (erdafitinib) in combination with cetrelimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, compared to BALVERSA® monotherapy in patients with locally advanced or metastatic urothelial carcinoma (mUC) with fibroblast growth factor receptor (FGFR)3 or FGFR2 genetic alterations who are ineligible for cisplatin, a current standard of care treatment for mUC. The results were highlighted in an oral presentation at t...
Source: Johnson and Johnson - September 17, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Tech Companies Are Transforming People ’s Bedrooms Into ‘Virtual Hospitals.’ Will It Last Post-COVID?
When Curtis Carlson started having back pain this spring, he tried to put off seeing a doctor. The COVID-19 pandemic was raging, his job at a transitional housing organization in Ukiah, Calif. was busier than ever amid the economic collapse, and a hospital seemed like the last place he wanted to be.
But when he finally took himself to the emergency room and he was diagnosed with a kidney infection, Carlson figured he would have no choice but to stay. Instead, his doctors told him about a new program that would allow him to finish the rest of his hospital care at home, with a medical team monitoring him virtually around th...
Source: TIME: Health - August 10, 2020 Category: Consumer Health News Authors: Abigail Abrams Tags: Uncategorized COVID-19 Source Type: news
Transition to exhaustion: clues for cancer immunotherapy
(Emory Health Sciences) Emory research on immune cells 'exhausted' by chronic viral infection provides clues on how to refine cancer immunotherapy. The Immunity paper defines a transitional stage in between stem-like and truly exhausted cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 3, 2019 Category: International Medicine & Public Health Source Type: news
Bladder Cancer | Medscape Bladder Cancer | Medscape
Bladder cancer is the second most common urologic malignancy. Transitional cell carcinoma accounts for more than 90% of cases; other types include squamous cell carcinoma and adenocarcinoma. In stage 1 disease, when the tumors are superficial, bladder cancer is treatable with transurethral resection and intravesical therapy. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 28, 2018 Category: Consumer Health News Tags: Resource Center Source Type: news
Biolase CEO Flynn steps down | Personnel Moves – April 13, 2018
Biolase (NSDQ:BIOL) said this week its CEO Harold Flynn has resigned from the company to pursue other interests, and that current CFO John Beaver will step in to act as interim CEO.
The transition will be made immediately, the Irvine, Calif.-based company said.
“I would like to thank Harold for the leadership and commitment he has demonstrated over the last three years. We are grateful for his contributions to product quality and for his steadfast dedication to Biolase. We thank him for his continued support and wish him all the best in this new phase of his professional career. We are pleased to have John take ...
Source: Mass Device - April 13, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Biolase Conventus Orthopaedics Endotronix Inc. Frequency Therapeutics General Electric Henry Schein Inc. mckeonproducts nsfhealthsciencescertification Omnicell Inc. PerkinElmer Inc. personnel-moves Source Type: news
Response and Development of Immune-Related Adverse Events in an 83-Year-Old Man With Metastatic Urothelial Cancer
An 83-year-old man was diagnosed with multiple low-grade transitional cell carcinomas over a 6-year period. A surveillance cystoscopy in year 7 showed high-grade noninvasive papillary urothelial carcinoma in the bladder trigone. A CT urogram showed a soft-tissue mass with diffuse enhancement in the lower pole of the left kidney, concerning for malignancy. (Source: CancerNetwork)
Source: CancerNetwork - March 15, 2018 Category: Cancer & Oncology Authors: Daniel P. Petrylak, MD Karishma K. Mehra, MD Tags: Bladder Cancer Genitourinary Cancers Oncology Journal Source Type: news
Jury Awards $22M in Asbestos-Contaminated Paint Case
A California jury recently awarded $22 million to the estate of a man exposed to asbestos-containing talc that was used in paint manufacturing, expanding the liability of those supplying the toxic ingredient.
Plaintiff Richard Booker, who worked as a paint maker throughout his career, died of mesothelioma in 2016. The lawsuit claimed Booker was exposed to asbestos while working for Dexter Midland Chemical Co. and Walter N. Boysen Paint Co.
The lucrative award includes $4.6 million in punitive damages, along with the initial judgement of $17.57 million for malice on the part of Vanderbilt Minerals and Imerys Talc America In...
Source: Asbestos and Mesothelioma News - January 2, 2018 Category: Environmental Health Authors: Daniel King Tags: Alameda County asbestos exposure asbestos-contaminated talc Cashmere Bouquet Colgate-Palmolive Dexter Midland Chemical Imerys Talc America mesothelioma lawsuit Richard Booker Vanderbilt Minerals Walter N. Boysen Paint Source Type: news
Immune Checkpoint Inhibitors Effective for Advanced Urothelial, Renal Cancers Immune Checkpoint Inhibitors Effective for Advanced Urothelial, Renal Cancers
In patients with advanced urothelial cell and renal cell cancers, immune checkpoint inhibitors (ICIs) are more effective and safer than conventional second-line treatment, a new systematic review from The Netherlands reports.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - July 18, 2017 Category: Pathology Tags: Hematology-Oncology News Source Type: news
Shape of prostate and compartments within may serve as cancer indicators
Preliminary computerized imaging reveals the shape of the prostate and a compartment within the gland -- called the transitional zone -- consistently differ in men with prostate cancer than those without the disease, according to new research. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 1, 2017 Category: Science Source Type: news
Shape of prostate and compartments within may serve as cancer indicators
(Case Western Reserve University) Preliminary computerized imaging reveals the shape of the prostate and a compartment within the gland -- called the transitional zone -- consistently differ in men with prostate cancer than those without the disease, according to new research led by Case Western Reserve University. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 1, 2017 Category: Cancer & Oncology Source Type: news
